A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia.

Manaye Tamrie DersehKiflom SolomonWasihun TameneWosenie BeneberuAshagrachew Tewabe Yayehrad Abyou Seyfu Ambaye

Published in: ClinicoEconomics and outcomes research : CEOR (2021)

This study showed that rivaroxaban is a cost effective alternative and substituting rivaroxaban for warfarin is acceptable to willingness to pay threshold.

Keyphrases

atrial fibrillation
venous thromboembolism
direct oral anticoagulants
oral anticoagulants
pulmonary embolism